Correspondence 0001628280-24-046657 from C4 Therapeutics, Inc. (CCCC) (CIK 0001662579) (CCCC)
C4 Therapeutics, Inc. (CCCC) (CIK 0001662579)
Date: Nov. 8, 2024 · CIK: 0001662579 · Accession: 0001628280-24-046657
AI Filing Summary & Sentiment
File numbers found in text: 333-282933
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Attention: Mr. Tim Buchmiller Requested Date: November 13, 2024 Requested Time: 4:05 p.m., Eastern Time
Dear Mr. Buchmiller:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), C4 Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 13, 2024, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Shoaib A. Ghias at (415) 733-6150.
If you have any questions regarding this request, please contact Shoaib A. Ghias of Goodwin Procter LLP at (415) 733-6150.
Sincerely,
C4 THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Document
November 8, 2024
VIA EDGAR
Office of Life Sciences Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Attention: Mr. Tim Buchmiller
Re:
C4 Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-3
File No. 333-282933
Acceleration Request
Requested Date:
November 13, 2024
Requested Time:
4:05 p.m., Eastern Time
Dear Mr. Buchmiller:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), C4 Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 13, 2024, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Shoaib A. Ghias at (415) 733-6150.
If you have any questions regarding this request, please contact Shoaib A. Ghias of Goodwin Procter LLP at (415) 733-6150.
Sincerely,
C4 THERAPEUTICS, INC.
/s/ Andrew J. Hirsch .
Andrew J. Hirsch.
President and Chief Executive Officer
cc: Jolie M. Siegel, C4 Therapeutics, Inc.
Edwin O’Connor, Esq., Goodwin Procter LLP
Shoaib A. Ghias, Esq., Goodwin Procter LLP
490 Arsenal Way, Suite 120, Watertown, MA 02472